Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) disclosed significant growth in its contract development and manufacturing organization (CDMO) business and strengthened liquidity in a shareholder letter from CEO Amir Reichman, according to a press release distributed via InvestorWire. The company reported approximately $8.1 million in committed customer orders as of October 20, 2026, a more than 300% increase from $1.9 million at year-end 2025. This surge was driven by a new agreement with a U.S.-based biopharmaceutical company that includes approximately $5.1 million in committed base service fees. The agreement also contemplates up to $5.85 million in additional, uncommitted services, bringing the combined potential opportunity to more than $10 million, subject to further agreements and project milestones.
The order growth matters because it signals rising demand for Scinai’s manufacturing services and validates its ability to attract large customers. The company also reported approximately $5.3 million in combined net proceeds from recent equity financings, including a standby equity purchase agreement drawdown and a private placement with warrant exercises. Management estimates that current cash resources and expected customer payments will support operations through late 2027, potentially extending into the third quarter of 2028 if additional project phases are activated and delivered. This extended runway reduces near-term financing risk and provides more time to execute on the CDMO strategy.
Scinai, a biopharmaceutical company focused on innovative immunology therapies, also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The company remains focused on expanding its CDMO customer base, improving facility utilization, and pursuing capital-efficient development of its NanoAb immunotherapy platform through grants and partnerships. For investors, the combination of strong order growth, improved liquidity, and an extended operating horizon may enhance confidence in the company’s ability to fund its dual strategy of contract manufacturing and proprietary pipeline development.
The full press release can be viewed at https://ibn.fm/3C1F4, and the latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI. The announcement was syndicated through IBN, a network that includes editorial syndication to 5,000+ outlets and social media distribution among its corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
